Prokaryotics Appoints Pamela Demain as CEO

Union, NJ – May 6, 2025 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, is pleased to announce the appointment of Pamela Demain as its new Chief Executive Officer.

Pam brings over four decades of leadership in the biopharmaceutical industry, including 35 years at Merck & Co., Inc., leading business development transactions as well as worldwide product management for anti-infectives. After leaving Merck, she served on the senior leadership team at The Medicines Company, responsible for the acquisition of the company by Novartis. In addition, in recent years, Pam has worked with many biotech companies successfully consummating strategic business development transactions. Throughout her career, Pam has demonstrated a commitment to driving growth, fostering innovation, and leading high-performing teams to develop transformative solutions. Her extensive background in negotiation of complex business transactions at all stages of development and commercialization, leading relationship development, strategic planning expertise, and global marketing/brand leadership will help guide Prokaryotics, Inc. into its next phase of expansion and success.

We are thrilled to welcome Pam Demain as the new CEO of Prokaryotics, Inc. Pam has played a key role at Prokaryotics, Inc. since its inception, leading the in-licensing of assets from Merck and serving as a member of the Board since Day 1. We are confident that she will accelerate our mission in bringing much needed new, safe, and effective therapeutics to the clinic.
-- Dr. Terry Roemer, PhD., Co-Founder, Chief Scientific Officer, and Chairman of the Board.

I am incredibly excited to serve as CEO of Prokaryotics, Inc. and work alongside such a talented and passionate team. My therapeutic area of expertise has always been in infectious diseases, both as the product leader for the launch of Primaxin/Tienam around the world as well as through the many business development deals executed in the infectious disease space. We continue to have a great need for new antibiotics given the high levels of antimicrobial resistance, and I have full confidence that the Prokaryotics team will deliver important and novel antibiotics which will save lives worldwide.
-- Pamela Demain, Chief Executive Officer, Prokaryotics, Inc.

As Prokaryotics welcomes Pam Demain, the company also takes this opportunity to thank Dr. Keith Bostian, former Prokaryotics, Inc. CEO, for his leadership and dedication during his tenure. Dr. Bostian played a crucial role in establishing Prokaryotics Inc. as a business entity and guiding the company in its earliest days of success.

We are extremely grateful to Keith who helped lay the foundation for the business we have built. Keith’s business and administrative guidance was invaluable, and we learned so much from him. It was helpful to have a veteran entrepreneur like Keith on the team when starting Prokaryotics.
-- Dr. Holly Sutterlin, Chief Operating Officer

About Prokaryotics, Inc.
Prokaryotics, Inc. is a biopharmaceutical company founded on Merck & Co., Inc. out-licensed antibiotic assets under development to treat life-threatening antimicrobial resistant (AMR) infections. Prokaryotics leverages its deep expertise in bacterial and fungal physiology, medicinal chemistry, collaborative spirit, and scientific passion to discover and develop new classes of antibiotics specifically targeting microbial cell wall and cell envelope biogenesis – the fundamental armor erected by these pathogens to naturally withstand the effects of antibiotic treatment and the human innate immune system.

Contact:
Holly Sutterlin
908 737-1922 x124
hsutterlin@prokaryotics.com